Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (471-480 of 594) with videos related to

Pageof 60
Sort By:
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-LifeKevin J Filipski, David J Edmonds, Michelle R Garnsey, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Research Square|June 29, 2026
Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsMinying Zhang, Barbara Nassif Rausseo, Peixin Jiang, et al.
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approachesEdwin R Parra, Pamela Villalobos, Carmen Behrens, et al.
Cancer|October 21, 2017
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinomaFrederico O Gleber-Netto, Mei Zhao, Sanchit Trivedi, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
JCI Insight|August 16, 2020
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunityKathleen M McAndrews, Dara P Dowlatshahi, Jianli Dai, et al.
Pageof 60

Showing results (471-480 of 594) with videos related to

Sort By:
Pageof 60
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
ACS Medicinal Chemistry Letters|October 18, 2023
Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-LifeKevin J Filipski, David J Edmonds, Michelle R Garnsey, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Research Square|June 29, 2026
Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsMinying Zhang, Barbara Nassif Rausseo, Peixin Jiang, et al.
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Journal for Immunotherapy of Cancer|June 7, 2018
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approachesEdwin R Parra, Pamela Villalobos, Carmen Behrens, et al.
Cancer|October 21, 2017
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinomaFrederico O Gleber-Netto, Mei Zhao, Sanchit Trivedi, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
JCI Insight|August 16, 2020
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunityKathleen M McAndrews, Dara P Dowlatshahi, Jianli Dai, et al.
Pageof 60